- Home
- BDTX vs SAVA Comparison
BDTX vs SAVA Comparison
Compare BDTX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- SAVA
- Stock Information
- Founded
- BDTX 2014
- SAVA 1998
- Country
- BDTX United States
- SAVA United States
- Employees
- BDTX N/A
- SAVA N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- SAVA Health Care
- Exchange
- BDTX Nasdaq
- SAVA Nasdaq
- Market Cap
- BDTX 144.9M
- SAVA 134.2M
- IPO Year
- BDTX 2020
- SAVA N/A
- Fundamental
- Price
- BDTX $2.48
- SAVA $2.58
- Analyst Decision
- BDTX Strong Buy
- SAVA Buy
- Analyst Count
- BDTX 4
- SAVA 3
- Target Price
- BDTX $15.50
- SAVA $111.50
- AVG Volume (30 Days)
- BDTX 476.4K
- SAVA 12.4M
- Earning Date
- BDTX 11-05-2024
- SAVA 11-07-2024
- Dividend Yield
- BDTX N/A
- SAVA N/A
- EPS Growth
- BDTX N/A
- SAVA N/A
- EPS
- BDTX N/A
- SAVA N/A
- Revenue
- BDTX N/A
- SAVA N/A
- Revenue This Year
- BDTX N/A
- SAVA N/A
- Revenue Next Year
- BDTX N/A
- SAVA N/A
- P/E Ratio
- BDTX N/A
- SAVA N/A
- Revenue Growth
- BDTX N/A
- SAVA N/A
- 52 Week Low
- BDTX $2.31
- SAVA $2.55
- 52 Week High
- BDTX $7.66
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- BDTX 43.96
- SAVA 23.06
- Support Level
- BDTX $2.43
- SAVA $2.78
- Resistance Level
- BDTX $2.66
- SAVA $3.28
- Average True Range (ATR)
- BDTX 0.16
- SAVA 0.24
- MACD
- BDTX 0.05
- SAVA 0.40
- Stochastic Oscillator
- BDTX 48.81
- SAVA 4.73
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.